Showing 3541-3550 of 5646 results for "".
- Hoya Vision Care Presents New Data on Myopia Management Spectacle Lenses at ARVOhttps://modernod.com/news/hoya-vision-care-presents-new-data-on-myopia-management-spectacle-lenses-at-arvo/2482800/Hoya Vision Care announced new clinical evidence from three key clinical studies highlighting the impact of 'Defocus Incorporated Multiple Segments (DIMS)' technology. The results were presented as part of the company’s 2025 scientific program, 'Exploring New Frontiers in Myopia
- EyeCool Therapeutics Announces Positive Results from Pilot Study in Patients with Chronic Ocular Surface Pain (COSP)https://modernod.com/news/eyecool-therapeutics-announces-positive-results-from-pilot-study-in-patients-with-chronic-ocular-surface-pain-cosp/2482799/EyeCool Therapeutics announced positive clinical data from a double-masked, randomized controlled pilot study of 31 patients in Australia evaluating the safety and efficacy of its investigational device (ETX-4143) for the treatment of Chronic Ocular Surface Pain (COSP). T
- LumiThera’s LIGHTSITE Phase 3B Extension Trial Shows Extended Vision Improvement in Dry AMDhttps://modernod.com/news/lumitheras-phase-3b-extension-trial-topline-results-show-extended-vision-improvement-in-dry-amd-subjects/2482796/LumiThera announced the topline results from the LIGHTSITE 3B extension trial, a prospective, open-label trial in dry age-related macular degeneration (AMD) subjects. The extension trial followed subjects that completed the pivotal LIGHTSITE 3 trial
- Ashvattha Therapeutics Presents Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Diseasehttps://modernod.com/news/ashvattha-therapeutics-present-positive-phase-2-results-for-subcutaneous-migaldendranib-in-retinal-vascular-disease-at-arvo/2482795/Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib (MGB), a novel subcutaneously administered nanomedicine treatment for retinal vascular diseases. Updated results were presented in a poster session at the
- Topcon Healthcare Launches IDHea to Fuel AI and Digital Health Innovation from the Eyehttps://modernod.com/news/topcon-healthcare-launches-idhea-to-fuel-ai-and-digital-health-innovation-from-the-eye/2482792/Topcon Healthcare announced the launch of the Institute of Digital Health (IDHea), an ocular data-as-a-service platform designed to accelerate AI research and digital health innovation. IDHea is designed to provide fast and secure access to unique real-world and clinical trial datasets,
- Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-datasets-on-the-potential-of-its-anti-vegf-therapy-dosed-twice-yearly-for-wet-amd/2482790/Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annua
- Moorfields Eye Hospital, UCL Institute of Ophthalmology and Topcon Partner to Launch New Medical Technology Companyhttps://modernod.com/news/moorfields-eye-hospital-ucl-institute-of-ophthalmology-and-topcon-partner-to-launch-new-medical-technology-company/2482786/Moorfields Eye Hospital NHS Foundation Trust, the UCL Institute of Ophthalmology (IoO), and Topcon Healthcare announced the launch of Cascader Limited, a new medical technology company that aims to transform the detection and management of eye disease through artificial intelligence (AI). Cascade
- Chengdu Origen and Vanotech Announce First Patient Dosed in Phase 1 Trial of Gene Therapy for Wet AMDhttps://modernod.com/news/chengdu-origen-and-vanotech-announce-first-patient-dosed-in-phase-1-trial-of-gene-therapy-for-wet-amd/2482781/Chengdu Origen Biotechnology and Vanotech announced that the first patient dosed in the VAN-2401 multicenter phase 1 clinical trial evaluating treatment with KH658 for patients with wet age-related macular degeneration (AMD). This multicenter, open-lab
- Oculis to Present Its Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/oculis-to-present-its-innovative-late-stage-pipeline-candidates-at-upcoming-ophthalmology-conferences/2482774/Oculis Holding AG announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Stud
- datosX and Topcon Healthcare Forge Strategic Partnership to Accelerate Digital Health Innovationhttps://modernod.com/news/datosx-and-topcon-healthcare-forge-strategic-partnership-to-accelerate-digital-health-innovation/2482770/datosX Digital Health Labs, a provider of digital health technology (DHT) testing and real-world validation for DHTs, announced an investment and strategic partnership with Topcon Healthcare. Financial terms of the deal were not disclosed. </